Emil D. Kakkis - 16 Apr 2026 Form 4 Insider Report for Ultragenyx Pharmaceutical Inc. (RARE)

Reporting relationship: President & CEO, Director
Issuer ticker: RARE
Reported as of: 16 Apr 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 20 Apr 2026, 17:19:30 UTC
Prior SEC filing: 03 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Karah Parschauer, attorney-in-fact

Key filing fact

Emil D. Kakkis filed Form 4 for Ultragenyx Pharmaceutical Inc. (RARE) on 20 Apr 2026.

Key facts

This page summarizes Emil D. Kakkis's Form 4 filing for Ultragenyx Pharmaceutical Inc. (RARE).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 20 Apr 2026, 17:19.

Change

Previous filing in this sequence was filed on 03 Mar 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001248093 Primary reporting owner

KAKKIS EMIL D

Relationship: President & CEO, Director
Address: C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO
Signature: /s/ Karah Parschauer, attorney-in-fact
Signature date: 20 Apr 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RARE transaction

Common Stock

Award

Transaction value
Shares: +76,745
Change %: +12%
Price: $0.000000^*
Shares after: 735,739
Date: 16 Apr 2026
Ownership: Direct
Footnotes: F1, F2

RARE holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 1,758,985
Date: 16 Apr 2026
Ownership: By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 200909
Footnotes: F3

RARE holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 200,000
Date: 16 Apr 2026
Ownership: By GRAT

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RARE transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +132,693
Change %
Price: $0.000000^*
Shares after: 132,693
Date: 16 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 132,693
Exercise price: $24.52
Footnotes: F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date

Footnote F2

Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.

Footnote F3

Amount of securities beneficially owned following reported transaction reflects the contribution of an aggregate of 400,000 shares previously owned indirectly by the reporting person to two grantor retained annuity trusts (each, a "GRAT").

Footnote F4

On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date.